Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.18.7869

Interleukin-12 and Interleukin-6 Gene Polymorphisms and Risk of Bladder Cancer in the Iranian Population  

Ebadi, Nader (Department of Medical Genetics, School of Medicine Tehran University of Medical Sciences)
Jahed, Marzieh (Varamin)
Mivehchi, Mohamad (Young Researchers' Club, Varamin - Pishva Branch, Islamic Azad University)
Majidizadeh, Tayebeh (Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology)
Asgary, Mojgan (Department of Pathology-Hasheminejad Clinical Research Developing Center, School of Medicine Tehran University of Medical Sciences)
Hosseini, Seyed Ali (Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.18, 2014 , pp. 7869-7873 More about this Journal
Abstract
Interleukin-12 (IL-12) as an antitumor and interleukin-6 (IL-6) as an inflammatory cytokine, are immunomodulatory products that play important roles in responses in cancers and inflammation. We tested the association between two polymorphisms of IL-12(1188A>C; rs3212227) and IL-6 (-174 C>G) and the risk of bladder cancer in 261 patients and 251 healthy individuals. We also investigated the possible association of these SNPs in patients with high-risk jobs and smoking habits with the incidence of bladder cancer. The genotype distributions of IL-6 (-174 C/G) genotype were similar between the cases and the control groups; however, among patients with smoking habits, the association between IL-6 gene polymorphism and incidence of bladder cancer was significant. After a control adjustment for age and sex, the following results were recorded: CC genotype (OR= 2.11, 95%CI=1.56-2.87, p=0.007), GC genotype (OR=2.18, 95%CI=1.16-4.12, p=0.014) and GC+CC (OR=2.6, 95%CI=1.43-4.47, p=0.011). A significant risk of bladder cancer was observed for the heterozygous genotype (AC) of IL-12 (OR=1.47, 95%CI=1.01-2.14, p=0.045) in all cases, and among smokers (AC) (OR=3.13, 95%CI=1.82-5.37, p=0.00014), combined AC+CC (OR=3.05, 95%CI=1.8-5.18, p=0.000015). Moreover among high risk job patients, there was more than a 3-fold increased risk of cancer in the carriers of IL-12 beta heterozygous (OR=3.7, 95%CI=2.04-6.57, p=0.000056) and combined AC+CC(OR=3.29, 95%CI=1.58-5.86, p=0.00002) genotypes as compared with the AA genotype with low-risk jobs. As a conclusion, this study suggests that IL-12(3'UTR A>C) and IL-6 (-174 C>G) genotypes are significantly associated with an increased risk of bladder cancer in the Iranian population with smoking habits and/or performing high-risk jobs.
Keywords
Bladder cancer; IL-12; IL-6; polymorphisms; high risk jobs; smoking; Iran;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Arnson Y, Shoenfeld Y, Amital H (2010). Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun, 34, 258-65.   DOI   ScienceOn
2 Belluco C, Olivieri F, Bonafe M, et al (2003). -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res, 9, 2173-6.
3 Bergholdt R, Ghandil P, Johannesen J, et al (2004). Genetic and functional evaluation of an interleukin-12 polymorphism (IDDM18) in families with type 1 diabetes. J Med Genet, 41, 39.   DOI
4 Chen H, Cheng S, Wang J, et al (2012). Interleukin-12B rs3212227 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep, 39, 10235-42.   DOI   ScienceOn
5 Chen MF, Lin PY, Wu CF, et al (2013). IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One, 8, 61901.   DOI
6 Colombo MP, Trinchieri G (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13, 155-68.   DOI   ScienceOn
7 Enewold L, Mechanic LE, Bowman ED, et al (2009). Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev, 18, 215-22.   DOI   ScienceOn
8 George DJ, Halabi S, Shepard TF, et al (2005). The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res, 11, 1815-20.   DOI   ScienceOn
9 Iliopoulos D, Jaeger SA, Hirsch HA, et al (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell, 39, 493-506.   DOI   ScienceOn
10 Grivennikov S, Karin M (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell, 13, 7-9.   DOI   ScienceOn
11 Hagiwara E, Takahashi KI, Okubo T, et al (2001). Cigarette smoking depletes cells spontaneously secreting Th(1) cytokines in the human airway. Cytokine, 14, 121-6.   DOI   ScienceOn
12 Iliopoulos D, Hirsch HA, Struhl K (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139, 693-706.   DOI   ScienceOn
13 Jaiswal PK, Singh V, Srivastava P, et al (2013). Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene, 519, 128-34.   DOI   ScienceOn
14 Kishimoto T (2005). Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol, 23, 1-21.   DOI   ScienceOn
15 Kobeissi LH, Yassine IA, Jabbour ME, et al (2013). Urinary bladder cancer risk factors: a Lebanese case- control study. Asian Pac J Cancer Prev, 14, 3205-11.   과학기술학회마을   DOI   ScienceOn
16 Lagmay JP, London WB, Gross TG, et al (2009). Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res, 15, 5234-9.   DOI   ScienceOn
17 Letasiova S, Medve'ova A, Sovcikova A, et al (2012). Bladder cancer, a review of the environmental risk factors. Environ Health, 11, 11.   DOI   ScienceOn
18 Morgan L, Cooper J, Montgomery H, et al (2006). The interleukin-6 gene -174G>C and -572G>C pro- moter polymorphisms are related to cerebral aneurysms. J Neurol Neurosurg Psychiatry, 77, 915-7.   DOI   ScienceOn
19 Liu RY, Song X, Chen P, et al (2012). Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals. Exp Ther Med, 3, 655-64.
20 Lin CY, Chien JW (2004). Increased interleukin-12 release from peripheral blood mononuclear cells in nephrotic phase of minimal change nephrotic syndrome. Acta Paediatr Taiwan, 45, 77-80.
21 Machado JC, Figueiredo C, Canedo P, et al (2003). A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 125, 364-71.   DOI   ScienceOn
22 Murakami S, Okubo K, Tsuji Y, et al (2004). Serum interleukin-12 levels in patients with gastric cancer. Surg Today, 34, 1014-9.   DOI
23 Noguchi Y, Jungbluth A, Richards EC, et al (1996). Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A, 93, 11798-801.   DOI
24 Otunctemur A, Koklu I, Ozbek E, et al (2014). Are Bladder Neoplasms More Aggresive in Patients with a Smokingrelated Second Malignancy? Asian Pac J Cancer Prev, 15, 4025-8.   DOI   ScienceOn
25 Qin Q, Xu X, Wang X, et al (2013). Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev, 14, 3117-21.   과학기술학회마을   DOI   ScienceOn
26 Smyth MJ, Dunn GP, Schreiber RD (2006). Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol, 90, 1-50.   DOI   ScienceOn
27 Rakoff-Nahoum S (2006). Why cancer and inflammation? Yale J Biol Med, 79, 123-30.
28 Sangro B, Melero I, Qian C, et al (2005). Gene therapy of cancer based on interleukin 12. Curr Gene Ther, 5, 573-81.   DOI
29 Schafer ZT, Brugge JS (2007). IL-6 involvement in epithelial cancers. J Clin Invest, 117, 3660-3.   DOI   ScienceOn
30 Šery O, Hladilová R, Novotny M, et al (2003). Association between -174 G/C polymorphism of interleukin-6 gene and alcoholism. Acta Neuropsychiatrica, 15, 257-61.   DOI   ScienceOn
31 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
32 Tan D, Wu X, Hou M, et al (2005). Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol, 174, 753-6.   DOI   ScienceOn
33 Sopori M (2002). Effects of cigarette smoke on the immune system. Nat Rev Immunol, 2, 372-7.   DOI   ScienceOn
34 Tahara E (1990). Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol, 116, 121-31.   DOI
35 Tamandani DM, Shekari M, Suri V (2009). Interleukin-12 gene polymorphism and cervical cancer risk. Am J Clin Oncol, 32, 524-8.   DOI   ScienceOn
36 Terry CF, Loukaci V, Green FR (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275, 18138-44.   DOI   ScienceOn
37 Waldner MJ, Foersch S, Neurath MF (2012). Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci, 8, 1248-53.   DOI
38 Wolf SF, Temple PA, Kobayashi M, et al (1991). Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol, 146, 3074-81.
39 Zhang H, Xu Y, Li L, et al (2012). The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int, 88, 447-53.   DOI   ScienceOn
40 Xu B, Niu XB, Wang ZD, et al (2011). IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep, 38, 2589-96.   DOI
41 Yang XQ, Xu C, Sun Y, et al (2013). Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9.   과학기술학회마을   DOI   ScienceOn
42 Zhu Z, Shen Z, Xu C (2012). Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm, 2012, 528690.
43 Yu Y, Wang W, Zhai S, et al (2012). IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol Biol Rep, 39, 8457-63.   DOI   ScienceOn
44 Zhang T, Wang H (2013). Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev, 14, 5269-73.   과학기술학회마을   DOI   ScienceOn
45 Zhou L, Yao F, Luan H, et al (2012). Functional polymorphisms in the interleukin-12 gene contribute to cancer risk: evidence from a meta-analysis of 18 case-control studies. Gene, 510, 71-7.   DOI   ScienceOn
46 Smith AJ, D'Aiuto F, Palmen J, et al (2008). Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem, 54, 841-50.   DOI   ScienceOn
47 Iranian Ministry of Health and Medical Education HD, Department of Prevention of Non Contagious Diseases (2012). Iranian annual of national cancer registration report 2009/2010, (In Persian).
48 Bozcuk H, Uslu G, Samur M, et al (2004). Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine, 27, 58-65.   DOI   ScienceOn